Activating KRAS mutation is prognostic only among patients who receive preoperative chemotherapy before resection of colorectal liver metastases

Georgios Antonios Margonis, Yuhree Kim, Kazunari Sasaki, Mario Samaha, Stefan Buettner, Neda Amini, Timothy M. Pawlik

Research output: Contribution to journal › Article › peer-review

8 Scopus citations

Fingerprint

Dive into the research topics of 'Activating KRAS mutation is prognostic only among patients who receive preoperative chemotherapy before resection of colorectal liver metastases'. Together they form a unique fingerprint.

Medicine & Life Sciences